Montpellier, May 3rd, 2023 – Quantum Surgical, a French medical robotics company, has received an extension of authorization from the US Food and Drug Administration (FDA) for its Epione® robot, which can now treat abdominal cancers. Over four million patients could benefit from Epione® treatment worldwide[1].
Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
Available in Europe and the United States, the Epione® robot has already been used to treat more than 150 patients with liver or kidney cancer.
The extension of the Food and Drug Administration (FDA) authorization allows the commercial sale and use of the Epione® robot in the United States to treat cancers of the entire abdomen. The abdomen is the space between the thorax and the pelvis, and includes in particular the following organs: liver, kidneys and adrenal glands, pancreas.
“We are very pleased to receive the FDA clearance. This decision allows physicians to now treat all abdominal tumors at an early stage and will accelerate the implementation of our innovative Epione® robotics solution in the United States. And ultimately, enable more patients to benefit from innovative and less invasive treatments” says Bertin Nahum, president and co-founder of Quantum Surgical.
This authorization is supported by clinical data from the Gustave Roussy Cancer Center. A demonstration video of the Epione robot is available here.
About Quantum Surgical
Quantum Surgical is a French medical robotics company and a major player in healthcare innovation. It develops solutions to address complex medical issues. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can therefore benefit from innovative, better targeted and less invasive treatments.
Co-founded in 2017 and with a team of 100+ employees, Quantum Surgical is based in Montpellier, with an international reach. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research.
[1] Source: Global Cancer Observatory
